Weight-Loss Drugs Boost Health-Linked Stocks.
TL;DR Summary
Eli Lilly's Mounjaro and Novo Nordisk's Ozempic, two weight-loss drugs, have become the most talked about and hyped pharmaceuticals in recent memory. The drugs are poised to become profit makers, with each company now having a market value of around $400 billion, despite their revenue being only 25% to 30% of that of industry leader Johnson & Johnson.
- Weight-Loss Drugs Will Be Blockbusters. Here's the Stock to Buy. Barron's
- Diabetes Drug Patients Use For Weight Loss May Have Heart Benefits NBC 5 Dallas-Fort Worth
- Watch out, Ozempic? Another diabetes drug leads to impressive weight loss in studies Yahoo News
- 'It's really, really important for me': Metro patients struggle to find diabetes drugs due to off-brand prescriptions KETV Omaha
- Weight loss drugs are a golden ticket for health-linked stocks IOL
Reading Insights
Total Reads
0
Unique Readers
8
Time Saved
0 min
vs 1 min read
Condensed
63%
157 → 58 words
Want the full story? Read the original article
Read on Barron's